Business Context and Reporting Period
Company: Corbus Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 20, 2015
Event: Entry into a Material Definitive Agreement with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT).
Key Financial Metrics and Obligations
This filing details a specific funding agreement rather than general financial performance metrics (revenue, profit, cash flow, or debt levels are not reported in this document).
- Total Award Funding: Up to $5 million.
- Immediate Funding: $1,250,000 received upon execution.
- Remaining Funding: Paid incrementally based on Phase 2 clinical trial milestones.
- Primary Use of Funds: Support for a first-in-patient Phase 2 clinical trial of Resunab for cystic fibrosis.
Material Changes and Financial Obligations
The agreement creates a direct financial obligation for the Company contingent on future commercialization or asset transfers. Key terms include:
- Commercialization Royalty: 5x the Award amount (up to $25 million), payable in three equal annual installments starting within 90 days of the first commercial sale.
- High-Volume Royalty: 1x the Award amount (up to $5 million) due in the first calendar year cumulative net sales exceed $500 million.
- Transfer/Change of Control Payment: Up to approximately $15 million if Resunab is transferred, sold, licensed (outside specific development purposes), or in a change of control transaction. This amount is credited against commercialization royalties.
- Termination: Either party may terminate for cause (e.g., failure to achieve milestones); payment obligations survive termination.
Guidance, Outlook, and Risks
Outlook: The funding supports the advancement of Resunab into a Phase 2 clinical trial for adults with cystic fibrosis and other respiratory conditions defined in the Field of Use.
Risks and Contingencies:
- Milestone Risk: Future funding is contingent on achieving specific clinical trial milestones.
- Commercialization Risk: Significant future cash outflows (up to $25 million) are triggered only upon commercial success.
- Termination Risk: The agreement can be terminated if the Company materially fails to achieve commercialization or development milestones.
Investor Verification Checklist
- Verify the specific milestones required to unlock the remaining $3.75 million of the Award.
- Confirm the exact definition of "Field of Use" to understand the scope of royalty obligations.
- Assess the Company's current cash position to determine if the $1.25 million immediate payment is sufficient to fund the Phase 2 trial without additional capital raises.
- Review the terms regarding the $15 million change of control payment to understand potential impacts on future M&A activity.